Intra-Cellular Therapies downgraded by Goldman with a new price target

8/22/22 7:12:27 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Goldman downgraded Intra-Cellular Therapies from Buy to Neutral and set a new price target of $49.00 from $64.00 previously

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ITCI

Date	Price Target	Rating	Analyst
2/24/2025	$140.00 → $132.00	Outperform → Neutral	Mizuho
1/31/2025	$119.00 → $132.00	Buy → Hold	Canaccord Genuity
9/6/2024	$68.00 → $92.00	Neutral → Overweight	Piper Sandler
1/3/2024	$83.00	Outperform	Robert W. Baird
12/11/2023	$75.00	Outperform	TD Cowen
4/20/2023	$80.00	Overweight	Morgan Stanley
8/22/2022	$64.00 → $49.00	Buy → Neutral	Goldman
7/7/2022	$74.00	Buy	Mizuho